Quality of life after radiation therapy of cerebral low-grade gliomas of the adult: Results of a randomised phase III trial on dose response (EORTC trial 22844)
Quality of life after radiation therapy of cerebral low-grade gliomas of the adult: Results of a randomised phase III trial on dose response (EORTC trial 22844)
复制标题
DOI：
10.1016/s0959-8049(98)00268-8
复制
发表时间：
1998-11-01
影响因子：
8.4
通讯作者：
Karim, ABMF
中科院分区：
文献类型：
--
作者：
Kiebert, GM;Curran, D;Karim, ABMF
1985年，EORTC放射治疗GO-OPERATION小组启动了一项随机的第三阶段研究，比较了高剂量(6.5周内59.4GY)和常规剂量(5周内45GY)放射治疗与常规技术在诊断为低级别脑胶质瘤的患者中的作用。这项研究的主要终点是生存。在两种治疗策略之间没有观察到生存率的差异，试验中包括一份由47个项目组成的生活质量问卷，评估一系列身体、心理、社会和症状领域，以衡量随着时间的推移治疗的影响。接受高剂量放射治疗的患者在放射治疗结束后往往报告功能水平较低，症状负担较重。这些组在放疗后即刻的疲倦/不适和失眠以及随机分组后7-15个月的休闲时间和情绪功能方面的差异具有统计学意义。这些结果表明：对于低度恶性脑胶质瘤的常规放射治疗，45Gy/5周的计划不仅节省了宝贵的资源，而且在不影响临床疗效的情况下节省了患者的长时间治疗。(C)1998爱思唯尔科学有限公司。保留所有权利。
In 1985, the EORTC Radiotherapy Go-operative Group launched a randomised phase III study comparing high-dose (59.4 Gy in 6.5 weeks) versus law-dose (45 Gy in 5 weeks) radiotherapy with conventional techniques in patients diagnosed with low-grade cerebral glioma. The primary endpoint of the study was survival. No difference in survival was observed between the two treatment strategies, A quality of Life (QoL) questionnaire consisting of 47 items assessing a range of physical, psychological, social, and symptom domains was included in the trial to measure the impact of treatment over time. Patients who received high-dose radiotherapy tended to report lower levels of functioning and more symptom burden following completion of radiotherapy. These group differences were statistically significant for fatigue/malaise and insomnia immediately after radiotherapy and in leisure time and emotional functioning at 7-15 months after randomisation. These findings suggest that: for conventional radiotherapy for low-grade cerebral glioma, a schedule of 45 Gy in 5 weeks not only saves valuable resources, but also spares patients a prolonged treatment at no loss of clinical efficacy. (C) 1998 Elsevier Science Ltd. All rights reserved.